Something still haunts Ed Weisbart, MD, from his days in the health insurance business.
It was 1999, and Weisbart was the medical director of a Chicago medical group that managed care for more than 140,000 people. The enterprise was running like a well-oiled machine — until one day, a man presented with a rare blood clotting disorder that would cost the company $1 million a year to treat. At that sum, one of its regional offices would likely go out of business.
